Arcturus Therapeutics Earnings Reports

Arcturus Therapeutics posted a net loss of $13.45 million for Q3 2025, reflecting lower collaboration revenues as KOSTAIVE progresses toward commercialization. However, the company maintained a solid cash position and reported progress in its pipeline, including ARCT-032 for cystic fibrosis.

For Q2 2025, Arcturus Therapeutics posted total revenue of $28.3M, driven mainly by strategic alliances and grant revenue, with a narrowed net loss of $9.18M. Operating expenses fell sharply due to reduced manufacturing costs and lower payroll, while the company maintained a strong cash position of $253.4M including restricted cash.

Arcturus Therapeutics reported a decrease in revenue and a smaller net loss for the first quarter of 2025 compared to the same period in 2024. The company is prioritizing its mRNA therapeutics pipeline, which is expected to extend the cash runway into 2028.

Arcturus Therapeutics reported Q4 2024 revenue of $22.8 million, down from $30.9 million in Q4 2023, mainly due to lower milestone achievements from the CSL agreement. The company posted a net loss of $30.0 million compared to $11.7 million in the prior year quarter, with EPS decreasing to -$1.11 from -$0.44. Operating expenses increased to $56.2 million, driven by higher research and development costs.

Arcturus Therapeutics reported its Q3 2024 financial results, featuring a revenue of $41.7 million and a net loss of $6.9 million, or ($0.26) per diluted share. The company achieved a $25 million commercial milestone with the first sale of KOSTAIVE® in Japan and anticipates another milestone related to potential European approval in the first quarter of 2025. The company's cash runway is expected to extend through the first quarter of fiscal year 2027.

Arcturus Therapeutics reported a revenue of $49.9 million for the second quarter of 2024, a significant increase of $39.4 million compared to the same period in 2023. The net loss for the quarter was $17.2 million, or ($0.64) per diluted share, compared to a net loss of $52.6 million, or ($1.98) per diluted share in the second quarter of 2023.